|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM116177845 |
| 003 |
DE-627 |
| 005 |
20231222173754.0 |
| 007 |
tu |
| 008 |
231222s2001 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0388.xml
|
| 035 |
|
|
|a (DE-627)NLM116177845
|
| 035 |
|
|
|a (NLM)11726223
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Zhou, H
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Efficacy and mechanisms of action of rmB7.2-Ig as an antitumor agent in combination with Adriamycin and Cytoxan chemotherapy
|
| 264 |
|
1 |
|c 2001
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 10.01.2002
|
| 500 |
|
|
|a Date Revised 16.11.2017
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a (c)2001 Elsevier Science.
|
| 520 |
|
|
|a The efficacy of chemotherapy for cancer is often limited by toxicity. Immune approaches to cancer immunotherapy, while promising for specificity and long-term protection, have not typically proven potent enough to generate significant therapeutic responses. We have shown therapeutic benefit using recombinant murine B7.2-Ig (rmB7.2-Ig) in murine tumor models. Efficacy was dependent on immune activity and was not associated with toxicity. Recently, the efficacy of rmB7.2-Ig was demonstrated in leukemia tumor models in combination with chemotherapeutic agents. To further explore the potential of this approach, we evaluated the efficacy in solid tumor models of rmB7.2-Ig given in combination with chemotherapeutics commonly used in clinical practice, testing the effects of dose and schedule. RmB7.2-Ig in combination with some chemotherapeutics enhances the activity and efficacy of reduced chemotherapeutic doses. However, the relative timing of chemotherapy and rmB7.2-Ig dosing can be important. Investigation of mechanisms of action based on histological studies suggests that inflammatory as well as T cell mechanisms comprise the response. Additional studies of mice deleted of B7.1, B7.2, and CTLA-4 suggest that the enhanced response induced by rmB7.2-Ig may not be mediated through CD28 ligation alone. The efficacy suggests potential for recombinant human B7.2-Ig as an adjuvant to chemotherapy in promoting immune-mediated mechanisms to augment the activity of chemotherapy
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Antigens, CD
|2 NLM
|
| 650 |
|
7 |
|a B7-2 Antigen
|2 NLM
|
| 650 |
|
7 |
|a CD86 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Cd86 protein, mouse
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin Heavy Chains
|2 NLM
|
| 650 |
|
7 |
|a Membrane Glycoproteins
|2 NLM
|
| 650 |
|
7 |
|a Recombinant Fusion Proteins
|2 NLM
|
| 650 |
|
7 |
|a Doxorubicin
|2 NLM
|
| 650 |
|
7 |
|a 80168379AG
|2 NLM
|
| 650 |
|
7 |
|a Cyclophosphamide
|2 NLM
|
| 650 |
|
7 |
|a 8N3DW7272P
|2 NLM
|
| 700 |
1 |
|
|a Sequeira, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Goad, M E
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Erickson, J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wong, A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Clark, E
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dunussi-Joannopoulos, K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, R C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Friedrich, S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hayes, L L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wolf, S F
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 101(2001), 3 vom: 07. Dez., Seite 303-14
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:101
|g year:2001
|g number:3
|g day:07
|g month:12
|g pages:303-14
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 101
|j 2001
|e 3
|b 07
|c 12
|h 303-14
|